International Journal of Clinical Pharmacy

, Volume 37, Issue 5, pp 734–738 | Cite as

Impact of a pharmacotherapy plan to improve adherence for patients with type-2 diabetes and hypertension in a Chilean hospital

  • Alejandra Soto
  • Ximena Avila
  • Pia Cordova
  • Pola Fernandez
  • Mariela Lopez
  • Lorenzo A. Villa
  • Felipe Morales
Short Research Report


Background Non-adherence to prescribed treatment is a principle cause of treatment failure in patients with chronic diseases, such as type 2 diabetes mellitus (T2DM) and hypertension. Improved patient monitoring and education have been shown to improve adherence and clinical outcomes. Objective This study evaluates the impact of a pharmacotherapy optimization plan centered on patient education that was implemented at a hospital in Arauco, Chile. Methods A prospective study was conducted using 50 randomly selected patients diagnosed with both T2DM and hypertension. Each patient participated in three successive interview sessions over 6 months. At each session, the following variables were evaluated by a pharmacist: blood pressure, HbA1c, adherence to prescribed medication, and patient knowledge of disease. Results Significant decreases were observed for HbA1c (<0.001), and SBP (<0.001), with stronger and more significant decreases observed for females. Patient adherence to prescribed medication also improved, but not significantly. The number of patients with full knowledge of their diseases increased significantly (p < 0.001) from 10 to 66 %. Conclusion This study suggests that the incorporation of a pharmacotherapeutic optimization plan for patients with chronic diseases can have a positive impact on the control of chronic diseases, such as T2DM and hypertension.


Chile Medication adherence Patient education Pharmacotherapeutic optimization plan 



The authors would like to thank the staff of Hospital San Vicente for facilitate the premises to run this study. We acknowledge the participation of Mr. Michael Levengood M.Sc. in the process of editing of this paper.


This study was not funded by any grant.

Conflicts of interest



  1. 1.
    Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74–109.CrossRefPubMedGoogle Scholar
  3. 3.
    Ministerio de Salud Chile. Encuesta Nacional de Salud 2009–2010. National Health Survey 2009–2010. Ministerio de Salud, Gobierno de Chile; 2011 3 Sept 2015.
  4. 4.
    Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM. Adherence in chronic disease. Annu Rev Nurs Res. 2000;18:48–90.PubMedGoogle Scholar
  5. 5.
    Ministerio de Salud Chile. Guia Clinica Hipertension Arterial Primaria o esencial en personas de 15 años y mas. Clinical guidelines for primary hypertension in patients 15 years and older. Ministerio de Salud, Gobierno de Chile; 2005.Google Scholar
  6. 6.
    Ministerio de Salud Chile. Guia Clinica Diabetes Mellitus tipo 2. Clinical guidelines for type 2 diabetes mellitus. Ministerio de Salud, Gobierno de Chile; 2010.Google Scholar
  7. 7.
    Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071–82.CrossRefPubMedGoogle Scholar
  8. 8.
    Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health. 2013;23(2):112–9.CrossRefGoogle Scholar
  9. 9.
    de Castro-Cornejo ML, Rico-Herrera L, Padilla-Raygoza N. Effect of educational support on treatment adherence in patients with type 2 diabetes: an experimental study. Enferm Clínica. 2014;24(3):162–7.CrossRefGoogle Scholar
  10. 10.
    De Vries ST, Keers JC, Visser R, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J, et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014;76(2):134–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  • Alejandra Soto
    • 1
  • Ximena Avila
    • 2
  • Pia Cordova
    • 3
  • Pola Fernandez
    • 3
  • Mariela Lopez
    • 3
  • Lorenzo A. Villa
    • 3
  • Felipe Morales
    • 3
  1. 1.CESFAM BicentenarioAraucoChile
  2. 2.Pharmacovigilance UnitSan Vicente HospitalAraucoChile
  3. 3.Facultad de FarmaciaUniversidad de ConcepciónConcepciónChile

Personalised recommendations